Alchem International announced that it will continue to market and support Tropane Alkaloid APIs despite earlier reports.
Alchem International confirmed on Sept. 15, 2014 that it will not end market development and regulatory support of Tropane Alkaloid APIs, but will maintain production and regulatory (drug master file) support from its GMP production units.
"Whilst the tropane alkaloid family of APIs is a specialist business and difficult to manage within larger scale production facilities, Alchem International has invested in a suite of bespoke manufacturing and regulatory capabilities to support smaller-scale, as well as, large-scale API production and dossier support,” said Raman Mehta, CEO and president at Alchem International, in a press release.
Alchem International will be present at CPhI Worldwide 2014 in Paris located at booth 6T55.
Source: Alchem International
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.